2.55
+0.04(+1.59%)
Currency In USD
| Previous Close | 2.51 |
| Open | 2.48 |
| Day High | 2.67 |
| Day Low | 2.46 |
| 52-Week High | 12.74 |
| 52-Week Low | 1.61 |
| Volume | 504,135 |
| Average Volume | 2.45M |
| Market Cap | 95.43M |
| PE | -1.22 |
| EPS | -2.09 |
| Moving Average 50 Days | 2.93 |
| Moving Average 200 Days | 3.78 |
| Change | 0.04 |
If you invested $1000 in Metagenomi, Inc. Common Stock (MGX) since IPO date, it would be worth $247.33 as of February 05, 2025 at a share price of $2.55. Whereas If you bought $1000 worth of Metagenomi, Inc. Common Stock (MGX) shares 1 year ago, it would be worth $247.33 as of February 05, 2025 at a share price of $2.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
GlobeNewswire Inc.
Jan 16, 2025 1:55 PM GMT
MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platform in 2025 Leveraging MGX-001 Editing ApproachOn Track for One to Two Development Candidate N
Metagenomi Announces New Appointment to its Board of Directors
GlobeNewswire Inc.
Jan 15, 2025 1:55 PM GMT
EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that
Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2025 9:05 PM GMT
EMERYVILLE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that